Search

Objective: To determine risk factors of infections with piperacillin/tazobactam-resistant Escherichia coli in critical care patients., Design: Prospective, consecutive sample survey study., Setting: Surgical intensive care unit (ICU) in a university hospital., Patients: A consecutive series of 133 patients from whom culture results were positive for E. coli during their ICU stay., Interventions: None., Measurements and Main Results: Multivariate logistic regression analysis identified the following significant independent factors associated with the emergence of a piperacillin/tazobactam-resistant Escherichia coli: prior use of amoxicillin (odds ratio, 4.15) and amoxicillin/clavulanate (odds ratio, 3.25)., Conclusions: Treatment with amoxicillin or amoxicillin/clavulanate is a major risk factor for the detection of piperacillin/tazobactam-resistant E. coli in ICU patients.

In September 2023, France was one of the first countries that started a national immunisation campaign with nirsevimab, a new monoclonal antibody against respiratory syncytial virus (RSV). Using data from a network of paediatric intensive care units (PICUs), we aimed to estimate nirsevimab effectiveness against severe cases of RSV bronchiolitis in France. We conducted a case–control study based on the test‐negative design and included 288 infants reported by 20 PICUs. We estimated nirsevimab effectiveness at 75.9% (48.5–88.7) in the main analysis and 80.6% (61.6–90.3) and 80.4% (61.7–89.9) in two sensitivity analyses. These real‐world estimates confirmed the efficacy observed in clinical studies. [ABSTRACT FROM AUTHOR]

The article presents a study which estimates the disability and chronic condition's prevalence in intensive care units which admits both children and neonates. It states that it uses a cross-sectional study applying web questionnaire as a research design. It mentions that children of gestationally corrected age were incorporated in the research. It concludes that the chronic condition's prevalence in Neonatal Pediatric Care Unit (NPICU) and Pediatric Intensive Care Unit (PICU) was 67%.